Table 1. Effects of adiponectin on... | American Society of Hematology

Table 1.

Effects of adiponectin on proliferation of hematopoietic cell lines

Cell lineage/line	Origin	Proliferation (SI)^A	No. of viable cells (×10⁴/well)
Cell lineage/line	Origin	Proliferation (SI)^A	HSA	Adiponectin
Myeloid lineage
KG1	Myelogenous leukemia	0.97 ± 0.02	1.71 ± 0.15	1.61 ± 0.02
HL60	Promyelocytic leukemia	0.99 ± 0.06	3.60 ± 0.49	3.68 ± 0.22
THP1	Monocytic leukemia	0.38 ± 0.03^*	1.79 ± 0.08	0.76 ± 0.08^†
MO7E	Megakaryocytic leukemia	1.04 ± 0.06	2.30 ± 0.24	2.15 ± 0.22
KU812	Myelogenous leukemia	0.86 ± 0.04^*	1.44 ± 0.05	1.36 ± 0.04^*
F36p	Myelodysplastic syndrome	1.01 ± 0.05	2.65 ± 0.16	2.55 ± 0.20
U937	Histiocytic lymphoma	1.02 ± 0.05	2.47 ± 0.10	2.65 ± 0.18
M1	Myelogenous leukemia	0.73 ± 0.07^†	4.86 ± 0.25	2.13 ± 0.19^†
WEHI3	Myelomonocytic leukemia	0.90 ± 0.06^*	2.42 ± 0.22	1.98 ± 0.10
Erythroid lineage
K562	Erythroleukemia	0.99 ± 0.04	4.57 ± 0.53	4.17 ± 0.25
HEL	Erythroleukemia	1.02 ± 0.02	3.43 ± 0.26	3.25 ± 0.20
F36e	Myelodysplastic syndrome	0.97 ± 0.07	0.41 ± 0.04	0.43 ± 0.03
T-cell lineage
MOLT4	Lymphoblastic leukemia	1.01 ± 0.03	5.40 ± 0.20	5.55 ± 0.41
Jurkat	Lymphoblastic leukemia	1.03 ± 0.03	2.38 ± 0.08	2.55 ± 0.19
CCRF-CEM	Lymphoblastic leukemia	0.94 ± 0.02	1.87 ± 0.19	1.73 ± 0.06
EL4	Malignant lymphoma	0.99 ± 0.03	5.12 ± 0.06	4.80 ± 0.37
B-cell lineage
Nalm6	Lymphoblastic leukemia	1.04 ± 0.10	3.48 ± 0.06	3.22 ± 0.10
BALL	Lymphoblastic leukemia	0.62 ± 0.07^†	1.83 ± 0.05	0.81 ± 0.07^†
ONHL1	Malignant lymphoma	0.99 ± 0.04	1.92 ± 0.27	2.13 ± 0.10
OPM2	Plasma cell leukemia	0.98 ± 0.03	3.88 ± 0.18	4.00 ± 0.15

Cell lineage/line	Origin	Proliferation (SI)^A	No. of viable cells (×10⁴/well)
Cell lineage/line	Origin	Proliferation (SI)^A	HSA	Adiponectin
Myeloid lineage
KG1	Myelogenous leukemia	0.97 ± 0.02	1.71 ± 0.15	1.61 ± 0.02
HL60	Promyelocytic leukemia	0.99 ± 0.06	3.60 ± 0.49	3.68 ± 0.22
THP1	Monocytic leukemia	0.38 ± 0.03^*	1.79 ± 0.08	0.76 ± 0.08^†
MO7E	Megakaryocytic leukemia	1.04 ± 0.06	2.30 ± 0.24	2.15 ± 0.22
KU812	Myelogenous leukemia	0.86 ± 0.04^*	1.44 ± 0.05	1.36 ± 0.04^*
F36p	Myelodysplastic syndrome	1.01 ± 0.05	2.65 ± 0.16	2.55 ± 0.20
U937	Histiocytic lymphoma	1.02 ± 0.05	2.47 ± 0.10	2.65 ± 0.18
M1	Myelogenous leukemia	0.73 ± 0.07^†	4.86 ± 0.25	2.13 ± 0.19^†
WEHI3	Myelomonocytic leukemia	0.90 ± 0.06^*	2.42 ± 0.22	1.98 ± 0.10
Erythroid lineage
K562	Erythroleukemia	0.99 ± 0.04	4.57 ± 0.53	4.17 ± 0.25
HEL	Erythroleukemia	1.02 ± 0.02	3.43 ± 0.26	3.25 ± 0.20
F36e	Myelodysplastic syndrome	0.97 ± 0.07	0.41 ± 0.04	0.43 ± 0.03
T-cell lineage
MOLT4	Lymphoblastic leukemia	1.01 ± 0.03	5.40 ± 0.20	5.55 ± 0.41
Jurkat	Lymphoblastic leukemia	1.03 ± 0.03	2.38 ± 0.08	2.55 ± 0.19
CCRF-CEM	Lymphoblastic leukemia	0.94 ± 0.02	1.87 ± 0.19	1.73 ± 0.06
EL4	Malignant lymphoma	0.99 ± 0.03	5.12 ± 0.06	4.80 ± 0.37
B-cell lineage
Nalm6	Lymphoblastic leukemia	1.04 ± 0.10	3.48 ± 0.06	3.22 ± 0.10
BALL	Lymphoblastic leukemia	0.62 ± 0.07^†	1.83 ± 0.05	0.81 ± 0.07^†
ONHL1	Malignant lymphoma	0.99 ± 0.04	1.92 ± 0.27	2.13 ± 0.10
OPM2	Plasma cell leukemia	0.98 ± 0.03	3.88 ± 0.18	4.00 ± 0.15

Triplicate aliquots of cells (1 × 10⁴/well) were cultured in serum-free medium with 10 μg/mL adiponectin or human serum albumin (HSA), and their proliferation was examined by tritium-thymidine incorporation assay and by counting recovered viable cells. Tritium-thymidine incorporation was measured after 24 hours of culture, and the results were expressed as stimulation index (SI)^A, which was calculated as SI = (tritium-thymidine incorporation with adiponectin)/(tritium-thymidine incorporation with HSA). Recovered viable cell numbers were evaluated after 48 hours of culture by using trypan blue dye exclusion.

P < .05 and

†

P < .01 for the difference from control (HSA) values. The data shown are the mean ± SD value from 3 separate experiments.

View Large

This Feature Is Available To Subscribers Only